Highlights from the SABPA OC/LA 17th Annual Biomedical Forum: Representing some of Organizers, Speakers, Sponsors & Attendees
On April 26, 2025, the SABPA OC/LA 17th Annual Biomedical Forum, one of the three flagship professional forums organized by the Socal Association for Biomedical and Pharmaceutical Advancements (SABPA), convened successfully in Irvine, CA. More than 200 guests from academia, medical device, IVD and biopharmaceutical companies in Southern California and beyond participated in the forum. It was truly inspiring to see the life & medical sciences community come together for thoughtful discussion, collaboration, and innovation. The quality of the program, the diversity of perspectives, and the energy of the speakers and attendees made the forum an exceptional experience.
The event commenced with a welcome speech by Ms. Dongmei Huang, Vice President of SABPA and President of SABPA OC/LA for 2025-26. This year’s forum focused on Innovation and Compliance with a full day of panels and keynotes spotlighting advances in AI, wearable devices, biotech research, regulatory best practices and Entrepreneurship in the Digital Era.
Morning Momentum: Regulation Meets Innovation
In a landmark gathering of biomedical innovators, health tech leaders, and regulatory strategists, a powerful message emerged: the future of healthcare lies at the intersection of AI, continuous monitoring, and smart regulatory navigation.
Dr. Elliot Botvinick from UC Irvine introduced a next-generation implantable multi-analyte sensor, capable of monitoring a wide array of biomarkers — from glucose and lactate to potassium and insulin — every 13 seconds. Designed to function across all skin tones, the device promises to revolutionize chronic care and trauma response by offering real-time, continuous insights without the burden of frequent blood draws. The system’s foundation in spectroscopic sensing and miniaturized wireless technology points to the future where patient monitoring is both seamless and personalized.
On the regulatory front, Dr. Jay Vaishnav emphasized the critical role of early FDA strategy in launching Software as a Medical Device (SaMD). With AI tools becoming increasingly central to diagnostics and workflow optimization, she underscored the need for cybersecurity, human oversight, and post-market vigilance. Regulatory readiness, she said, is not just a compliance task — it’s a key differentiator for investors and clinicians alike.
Panel discussions on Small Business Innovation Research(SBIR) grants offered tactical guidance to startups navigating through a tough/increasingly challenging funding environment. Key advice included writing grant proposals with clarity, responding constructively to rejections, and embracing feedback. AI, while useful, should be used carefully in submissions — passion and scientific rigor must still come from the innovator.
AI also took center stage in drug development. Dr. Alex Zhavoronkov of Insilico Medicine shared how Generative AI and robotics are accelerating drug discovery by simulating biology and generating new therapeutic candidates — a breakthrough in aging and oncology research.
Dr. Binh Nguyen highlighted that in the evolving pharmaceutical landscape, ensuring the safety, efficacy, and quality of medicinal products is paramount. Quality Risk Management (QRM) has emerged as a critical strategy to proactively identify, assess, and mitigate risks throughout the product lifecycle—from development and manufacturing to distribution and post-market surveillance.
Sessions Explore Innovations in Dental Industry and In Vitro Diagnostics (IVD) Industry
During the lunch break, attendees had the opportunity to participate in three concurrent lunch-and-learn sessions, covering specialized topics offered by SABPA OC/LA sponsors:
Afternoon Spotlight: Generative AI, Wearables, Cell Therapy and Entrepreneurship in the Digital Era
In the realm of cancer therapy, Dr. Peter Wang introduced a remote-controlled CAR-T cell therapy using ultrasound to safely activate or deactivate treatment in solid tumors. Combined with CRISPR, this innovation opens new frontiers in non-invasive, real-time immunotherapy.
From the lab of Dr. Wei Gao came another futuristic development: wearable molecular sensors powered by sweat and AI. These devices target early diagnosis of metabolic diseases, stress monitoring, cancer drug dosing, and even hormone tracking — a noninvasive, continuous, and deeply personal approach to health.
Dr. Laura Li highlighted how AI is transforming genomic interpretation, reducing the cost and complexity of diagnosing rare diseases. Darren LaCour addressed shifting global strategies due to the EU’s Medical Device Regulation (MDR), urging early-stage companies to reconsider their clinical and regulatory entry points.
Closing the event, a forward-looking panel on entrepreneurship in the digital era—moderated by Yinghong Gao of Viva Biotech—brought together leaders from Ancora Medical, Accelerated Venture Partners, Amberstone Biosciences, and BOLD Capital Partners. The discussion highlighted the increasingly challenging investment landscape for digital health startups, where only 1 in 10 ventures now secure funding, a steep drop from 1 in 3 just a few years ago. Investors emphasized a shift toward greater selectivity, prioritizing robust clinical data, experienced advisory teams, and clear, differentiated value propositions. While AI remains a powerful enabler, panelists were clear: AI is a tool, not the business itself.
The Forum Highlighted Future Healthcare Innovations and Collaborative Strategies for Patient-Centered Care
The forum offered a clear vision for the future of healthcare, where new technologies like wearable sensors, AI-driven drug discovery, and advanced diagnostics work hand in hand with smart regulatory planning to improve patient care. From real-time health monitoring to targeted cancer treatments, the message was clear: innovation must be focused, backed by data, centered on patient needs, and meet federal and professional compliance regulation requirements.
But technology alone isn’t enough. In today’s tough funding environment, success also requires strong planning, solid clinical proof, and determined leadership. This event was a reminder and a call to action — encouraging everyone in healthcare to work together, adapt to, and lead the way toward smarter, safer, and more accessible care.
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]